Novavax Inc. (NASDAQ:NVAX) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Novavax Inc. (NASDAQ:NVAX) have earned an average rating of “Hold” from the eleven research firms that are presently covering the firm. Seven equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $6.60.
Several equities analysts have recently commented on the stock. FBR & Co restated an “outperform” rating and issued a $12.00 target price on shares of Novavax in a research report on Monday. Zacks Investment Research upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Wednesday, September 21st. Chardan Capital dropped their target price on shares of Novavax from $5.75 to $1.50 and set a “neutral” rating for the company in a research report on Tuesday, September 20th. S&P Equity Research dropped their target price on shares of Novavax from $1.44 to $1.17 in a research report on Friday, September 16th. Finally, Citigroup Inc. cut shares of Novavax from a “buy” rating to a “neutral” rating and dropped their target price for the company from $12.00 to $1.50 in a research report on Friday, September 16th.
In other Novavax news, SVP John Trizzino bought 46,000 shares of Novavax stock in a transaction on Thursday, September 22nd. The shares were purchased at an average cost of $2.17 per share, with a total value of $99,820.00. Following the acquisition, the senior vice president now directly owns 85,564 shares of the company’s stock, valued at approximately $185,673.88. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael A. Mcmanus, Jr. bought 30,000 shares of Novavax stock in a transaction on Wednesday, September 21st. The shares were acquired at an average cost of $1.61 per share, for a total transaction of $48,300.00. Following the completion of the acquisition, the director now directly owns 247,590 shares in the company, valued at $398,619.90. The disclosure for this purchase can be found here. Company insiders own 3.50% of the company’s stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/novavax-inc-nasdaqnvax-given-consensus-recommendation-of-hold-by-brokerages.html
A number of large investors have recently bought and sold shares of NVAX. Coldstream Capital Management Inc. raised its stake in Novavax by 17.5% in the second quarter. Coldstream Capital Management Inc. now owns 13,805 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 2,055 shares during the last quarter. Compagnie Lombard Odier SCmA acquired a new stake in Novavax during the second quarter worth $102,000. Veritable L.P. acquired a new stake in Novavax during the second quarter worth $102,000. BlackRock Inc. raised its stake in Novavax by 138.7% in the first quarter. BlackRock Inc. now owns 19,870 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 11,547 shares during the last quarter. Finally, Moors & Cabot Inc. acquired a new stake in Novavax during the second quarter worth $119,000. 79.84% of the stock is currently owned by hedge funds and other institutional investors.
Novavax (NASDAQ:NVAX) traded up 3.89% during mid-day trading on Monday, hitting $1.87. 7,107,753 shares of the stock traded hands. The company has a 50 day moving average price of $4.89 and a 200-day moving average price of $5.90. The stock’s market capitalization is $506.46 million. Novavax has a one year low of $1.16 and a one year high of $9.23.
Novavax (NASDAQ:NVAX) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.04. The firm earned $2.50 million during the quarter, compared to analyst estimates of $8.03 million. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. Novavax’s quarterly revenue was down 82.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. Equities analysts anticipate that Novavax will post ($1.09) earnings per share for the current fiscal year.
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.